IRB #

STUDY00019277

Title

A Phase 1b Study of ASP1948, Targeting an Immune Modulatory
Receptor, as a Single Agent and in Combination with Nivolumab in Subjects with Advanced Solid Tumors

Principal Investigator

Jacqueline Vuky

Study Purpose

The main purpose of the study is to determine at what dose the study drug (ASP1948) is safe and tolerated and how it is processed in the blood of participants with tumors that cannot be removed (unresectable) or have spread (metastasized) to a different part of the body.

Medical Condition(s)

locally-advanced (unresectable) or metastatic solid tumors

Eligibility Criteria

male and female subjects of 18 and older
locally advanced or metastatic solid tumor malignancy

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Up to 48 weeks of receiving the study drug and 45 weeks of follow-up time after completing the study drug.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Astellas Pharma Global Development, Inc.

Recruitment End

11/30/2023

Compensation Provided

No


Go Back